PSYCHOTHERAPY FOR ADOLESCENTS, CHildren AND ADULTS
The Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee voted overwhelmingly to reject MDMA-assisted therapy in the treatment of post traumatic stress disorder, or PTSD.
The FDA will issue its final decision on the matter in mid-August but in the majority of cases, the federal agency’s decisions align with the vote of the independent panelists on advisory committees.
Read moreThis psychiatric disorder, known for its high mortality rate, has long been a challenging condition to treat effectively.
The research, conducted at Monash University, revealed that psilocybin could improve cognitive flexibility and help maintain body weight in an animal model of AN.
Read moreTwo articles cover this recent update.
npr: Misconduct claims may derail MDMA psychedelic treatment for PTSD
Axios: Landmark review spotlights challenge of judging psychedelic therapies
Read moreReference to an intrinsic healing mechanism or an ‘inner healer’ is commonplace amongst psychedelic users.
Read moreBeckley Psytech Ltd, the private, clinical-stage biopharmaceutical company dedicated to improving the lives of people living with neuropsychiatric disorders by developing effective and rapid-acting psychedelic medicines, today announced the publication of a new paper in The Journal of Psychopharmacology which demonstrates the safety, tolerability and rapid-acting subjective effects of BPL-003, Beckley Psytech’s novel, synthetic, intranasal benzoate salt formulation of 5-MeO-DMT (also known as mebufotenin).
Read moreIn a new study, researchers found that psychological flexibility, several facets of mindfulness, and values-congruent living significantly improved following psilocybin and were maintained through week 16.
Additionally, improvements in psychological flexibility and experiential acceptance were strongly associated with reductions in depression severity following psilocybin.
Keep reading for the full article at Nature.com
Read moreKeep reading for an interview with a researcher of mystical experiences.
Read moreNew research into the dying brain suggests the line between life and death may be less distinct than previously thought.
Read moreIn the twin data researchers reviewed, mania was also strongly correlated with a genetic predisposition to schizophrenia and to bipolar I disorder.
In other words, those who experienced manic symptoms after psychedelic use may have been more genetically prone to mental illnesses.
Read moreAlso the trial’s rate of full remission, or a full cessation of symptoms, was five times greater than the placebo group, a marked and compelling difference in treatment outcomes.
Read more